PPWR Quick Guide: EU PPWR Compliance Steps for Medical Device and IVD Manufacturers

TL;DR

The EU PPWR applies from 12 August 2026 with no transition period for roles, substance restrictions, or the conformity framework. Medical device and IVD manufacturers need to determine their role, prepare technical documentation. Non-EU manufacturer that sales online directly to end users in EU members states, need to appoint an EPR representative for each member state. Labelling, recyclability, and recycled content requirements follow later, with partial exemptions for contact-sensitive packaging.

The PPWR (Regulation (EU) 2025/40) is the EU regulation governing packaging sustainability and extended producer responsibility, and it applies to medical device and IVD packaging from 12 August 2026. There is no grace period for role assignment or the conformity assessment from that date. Any manufacturer placing medical devices or in-vitro diagnostics on the EU market needs to know by then whether the regulation applies to them, and in which role. Not every obligation starts at the same time, but missing the first steps now risks a distribution ban from August onward. This guide covers the EU PPWR compliance steps for businesses in the medical device and IVD sector under the PPWR regulation in more depth than a simple deadline overview, because role allocation and the medical device exceptions are where most questions come up in practice.

The EU PPWR Timeline and Implementation Schedule

From 12 August 2026, the role definitions and the conformity framework under the PPWR apply in full, with no transition period. Substance restrictions on PFAS, heavy metals, phthalates and bisphenols also apply from that date, as do the basic information and reporting duties.

The heavier sustainability duties phase in later. Contact-sensitive packaging benefits from partial exemptions here, covered further below.

In Germany, the underlying structure is not new. Registration in the LUCID packaging register and system participation are already mandatory under the Packaging Act (VerpackG). The PPWR mainly expands the roles and duties on top of that. For German operators, this often means updating existing registrations rather than starting from zero.

Step Zero: Is Your Item Packaging at All?

Before any role can be assigned, it must be clear whether an item counts as packaging under the PPWR. For medical devices, this is not a formality. IV bags and syringes, for example, are not packaging, even when placed on the market pre-filled with medicine or saline. They are an integral part of the product itself (Art 3(1)(1)). Sterile barrier systems and secondary or transport packaging normally do count as packaging, so the roles and duties apply to them. This classification should be made separately for each packaging item, since it decides which duties and exemptions apply.

Two Roles, Two Sets of Duties: Manufacturer and Producer

The PPWR separates two roles that are easily confused in practice: the Manufacturer and the Producer.

A rule of thumb applies in practice: if the Manufacturer is based in the Member State where the packaging becomes waste, it is usually also the Producer there, since no one sits earlier in the chain. If the Manufacturer is based abroad, the first domestic company in the chain, whether importer or distributor, becomes the Producer instead. This domestic precedence decides who finances the waste management and cannot be reassigned by contract.

In practice: an example makes the distinction concrete.

A manufacturer based outside the EU sells sterile packed medical device by distance sale, directly to a hospital in Germany. PPWR role allocation does not depend on the device's risk class, only on the sales route. Without an intermediate domestic distributor, the foreign manufacturer automatically becomes the Producer in Germany and must appoint a EPR representative there. If the same sale instead runs through a distributor established in Germany that resells to the hospital, the Producer role shifts to that distributor. The foreign Manufacturer remains responsible for the conformity of the packaging in both cases, but EPR financing sits with a different party depending on the sales route.

EU PPWR Compliance Steps for Businesses: The Checklist Before 12 August 2026

• Map your packaging portfolio: own brands and imports, each recorded by type (primary, secondary, transport), material and weight
• Decide your role per Member State, not once for the entire EU, since domestic precedence can play out differently by country
• Collect supplier data on weight and material, including from suppliers outside Europe, since this data is needed for conformity and reporting
• Check substance restrictions: PFAS, heavy metals, phthalates and bisphenols, with no exemption even for contact-sensitive packaging
• Prepare the technical documentation under Annex VII and the EU Declaration of Conformity under Art 39; legal responsibility for this sits solely with the Manufacturer under Art 15, even if a supplier drafts parts of it
• In case of Extended Producer Responsibility: check your national registrations on currency, add all relevant brand names, and adjust or expand system participation contracts
• Report volumes 1:1 and mirror each report to national producer registers, keeping full documentation for the year-end report
• Appoint representatives wherever a domestic establishment is missing: a conformity representative (Art 3(1)(19)) once EU-wide for the Manufacturer role (voluntary), and an EPR representative separately in each affected Member State for the Producer role (mandatory)

These two representative roles are easy to conflate but serve different functions. A representative of the manufacturer acts once, EU-wide, on behalf of a Manufacturer established outside the EU, to keep the EU declaration of conformity and the technical documentation at the disposal of the national competent (Art. 17). An EPR representative (Art. 45.3) is appointed separately in each Member State where a Producer has EPR duties but no establishment, and covers only the waste-financing side.

Special Rules for Medical Devices and IVDs

For PPWR medical device packaging, contact-sensitive classification is not automatic and has to be assessed for each packaging type individually. Packaging whose properties can affect the safety, integrity or performance of a medical device or IVD counts as contact-sensitive, typically the sterile barrier system and more rarely secondary or transport packaging.

For contact-sensitive packaging, the PPWR provides targeted relief: exemptions on recyclability (Art 6, reviewed by 1 January 2035) and on recycled content (Art 7, reviewed by 12 February 2032), labelling relief under Art 12(11) where there is no space or a safety risk would result, and relief in the area of documentation under Art 15.

What still applies unchanged is the substance restrictions and packaging minimisation under Art 10 from 2030, though the latter only insofar as sterility and protective function are not compromised. Labelling from August 2028, registration, reporting and EPR financing under each national system all remain fully applicable. Any PPWR labelling or marking must not replace, obscure, or be confused with the CE mark or with sterility information required under MDR or IVDR.

On retention periods, the stricter regime prevails where it applies: MDR and IVDR retention periods of 10 to 15 years override the PPWR's single-use retention term of 5 years; for reusable packaging, the PPWR term is already 10 years. Health risks arising from packaging are reported to the MDR and IVDR authorities, not to PPWR market surveillance (Art 58). Custom-made transport packaging for configurable medical devices is also exempt from conformity assessment and from the retention duty for technical documentation.

Technical Documentation and the Declaration of Conformity: What Goes Into Them

The technical documentation under Annex VII must make the conformity assessment traceable and include an analysis of the risks of non-conformity. It should cover a general description of the packaging and its intended use, design documents, manufacturing drawings and material specifications, and a list of the harmonised standards or common specifications applied. Where standards were not applied, or only partly applied, the documentation must describe the solution adopted instead. It should also include a qualitative description of how the assessments under Articles 6, 10 and 11 were carried out, together with test reports.

The EU Declaration of Conformity under Annex VIII is issued under the sole responsibility of the Manufacturer and must include, among other elements, the unique identification of the packaging, the name and address of the Manufacturer and, where applicable, the representative, and the Union legislation and standards applied.

Frequently Asked Questions

Does the PPWR Declaration of Conformity replace the MDR or IVDR Declaration of Conformity?
No. The EU Declaration of Conformity under Art 39 PPWR is a independent declaration that covers only the packaging. It exists alongside the Declaration of Conformity for the medical device or IVD itself, not in place of it.

Can the Manufacturer and the Producer be the same company?
Yes, and this is the standard case when the Manufacturer is based in the Member State where the packaging becomes waste. If the Manufacturer is based abroad, the first domestic company in the chain takes on the Producer role under domestic precedence.

What happens if a foreign Producer has not appointed an EPR representative by 12 August 2026?
A distribution ban applies to the affected packaging.

Does the contact-sensitive packaging exemption cover all medical device packaging?
No. Contact-sensitive classification has to be assessed for each packaging type individually. Secondary and transport packaging is generally not contact-sensitive and does not benefit from the relief.

How long does the technical documentation need to be kept?
Generally 5 years for single-use packaging and 10 years for reusable packaging from the date placed on the market. Where MDR or IVDR retention periods of 10 to 15 years apply, those take precedence over the PPWR term.

Conclusion

12 August 2026 marks the start of PPWR implementation, not its conclusion. Companies that clarify roles, substance restrictions and conformity documentation now avoid a distribution ban, and still have time to prepare for the later duties such as labelling, recyclability and minimisation.

Article numbering can differ slightly between sources discussing the PPWR. This guide follows the numbering used in MedNet EC-REP's internal source material, and other overviews cite some of the same points under different sub-numbers. For any binding step, verify the article numbering against the adopted text of Regulation (EU) 2025/40 directly.

As an EU Authorized Representative for medical devices, IVDs and other regulated product categories, we track regulatory developments such as the PPWR on behalf of our clients. If you have questions about your EU market access or would like to review your existing registration, get in touch.

PPWR Quick Guide - What medical device and IVD manufacturers must do by 12 August 2026 (Stephanie Vorwerk, MedNet EC-REP); Regulation (EU) 2025/40, Art 3, 5, 6, 7, 10, 12, 15, 38, 39, 44, 45, Annex VII/VIII; VerpackDG § 5